[go: up one dir, main page]

TNSN00092A1 - Composes nouveaux antagonistes de npy, procede pour leur preparation et compositions pharmaceutiques les contenant - Google Patents

Composes nouveaux antagonistes de npy, procede pour leur preparation et compositions pharmaceutiques les contenant

Info

Publication number
TNSN00092A1
TNSN00092A1 TNTNSN00092A TNSN00092A TNSN00092A1 TN SN00092 A1 TNSN00092 A1 TN SN00092A1 TN TNSN00092 A TNTNSN00092 A TN TNSN00092A TN SN00092 A TNSN00092 A TN SN00092A TN SN00092 A1 TNSN00092 A1 TN SN00092A1
Authority
TN
Tunisia
Prior art keywords
preparation
pharmaceutical compositions
compositions containing
antagonist compounds
npy antagonist
Prior art date
Application number
TNTNSN00092A
Other languages
English (en)
Inventor
Hammond Marlys
Louis Elliott Richard
Frederick Hank Richard
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Publication of TNSN00092A1 publication Critical patent/TNSN00092A1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Child & Adolescent Psychology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

L'INVENTION CONCERNE UN COMPOSE DE FORMULE I : DANS LAQUELLE Y REPRESENTE DIVERS RADICAUX, ET L ET M REPRESENTENT LE CARBONE OU L'AZOTE. ELLE CONCERNE EGALEMENT UN PROCEDE POUR SA PREPARATION ET UNE COMPOSITION PHARMACEUTIQUE LE CONTENANT. APPLICATION : UTILISATION DE CE COMPOSE OU DE CETTE COMPOSITION, COMME ANTAGONISTE DE NPY, POUR LE TRAITEMENT DE DIVERSES MALADIES A MEDIATION PAR NPY, Y COMPRIS L'OBESITE.
TNTNSN00092A 1999-04-30 2000-04-26 Composes nouveaux antagonistes de npy, procede pour leur preparation et compositions pharmaceutiques les contenant TNSN00092A1 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US13202999P 1999-04-30 1999-04-30

Publications (1)

Publication Number Publication Date
TNSN00092A1 true TNSN00092A1 (fr) 2005-11-10

Family

ID=22452122

Family Applications (1)

Application Number Title Priority Date Filing Date
TNTNSN00092A TNSN00092A1 (fr) 1999-04-30 2000-04-26 Composes nouveaux antagonistes de npy, procede pour leur preparation et compositions pharmaceutiques les contenant

Country Status (12)

Country Link
US (2) US6355635B1 (fr)
AR (1) AR028824A1 (fr)
AU (1) AU2935200A (fr)
CO (1) CO5170414A1 (fr)
GT (1) GT200000057A (fr)
HN (1) HN2000000041A (fr)
MA (1) MA26730A1 (fr)
PA (1) PA8493701A1 (fr)
PE (1) PE20010118A1 (fr)
TN (1) TNSN00092A1 (fr)
UY (1) UY26130A1 (fr)
WO (1) WO2000066578A1 (fr)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR032292A1 (es) 1999-12-16 2003-11-05 Schering Corp Imidazoles sustituidos, composiciones farmaceuticas y el uso de dichos imidazoles para la manufactura de un medicamento para los tratamientos de desordenes en la alimentacion
US6894063B2 (en) * 2000-09-14 2005-05-17 Schering Corporation Substituted urea neuropeptide Y Y5 Receptor antagonists
US20050043256A1 (en) * 2001-07-30 2005-02-24 Isis Pharmaceuticals, Inc. Antisense modulation of stearoyl-CoA desaturase expression
US20050107411A1 (en) * 2001-12-17 2005-05-19 Macneil Douglas J. Method for treating circadian rhythm disruptions
BR0307429A (pt) * 2002-02-05 2004-12-28 Novo Nordisk As Composto, uso do mesmo, composição farmacêutica, e, método para o tratamento de distúrbios ou doenças relacionadas com receptor de histamina h3
EP1496838B1 (fr) 2002-03-12 2010-11-03 Merck Sharp & Dohme Corp. Amides substitues
EP1556373A1 (fr) * 2002-10-18 2005-07-27 Pfizer Products Inc. Ligands des recepteurs des cannabinoides et applications de ceux-ci
WO2005000217A2 (fr) * 2003-06-06 2005-01-06 Merck & Co., Inc. Polytherapie permettant de traiter la dyslipidemie
WO2005009976A1 (fr) 2003-07-29 2005-02-03 Novo Nordisk A/S Pyridazinyl-piperazines et leur utilisation en tant que ligands du recepteur histaminique h3
WO2005030208A1 (fr) * 2003-09-26 2005-04-07 Pfizer Products Inc. Utilisation d'un antagoniste du recepteur y5 du npy pour le traitement des troubles du rythme circadien
MXPA06003393A (es) * 2003-09-26 2006-06-08 Pfizer Prod Inc Tratamiento de trastornos neurologicos relacionados con alteraciones del sueno de movimientos oculares rapidos (rem) con antagonistas de receptor npy y5.
US7319108B2 (en) 2004-01-25 2008-01-15 Sanofi-Aventis Deutschland Gmbh Aryl-substituted heterocycles, process for their preparation and their use as medicaments
DE102004003812A1 (de) * 2004-01-25 2005-08-11 Aventis Pharma Deutschland Gmbh Arylsubstituierte Heterozyklen, Verfahren ihrer Herstellung und ihre Verwendung als Arzneimittel
WO2005103039A1 (fr) * 2004-04-15 2005-11-03 Neurocrine Biosciences, Inc. 2- (3-aminopyrrolidin-1-yl) pyridines utilisees comme antagonistes du recepteur de l'hormone concentrant la melanine, et compositions et procedes associes
US20060039890A1 (en) * 2004-08-20 2006-02-23 Renshaw Perry F Treatment of psychological and cognitive disorders using a cholesterol -lowering agent in combination with an antidepressant
MX2007003325A (es) 2004-09-20 2007-06-05 Xenon Pharmaceuticals Inc Derivados heterociclicos y su uso como inhibidores estearoil-coa-desaturasa.
AU2005286648A1 (en) 2004-09-20 2006-03-30 Xenon Pharmaceuticals Inc. Heterocyclic derivatives and their use as stearoyl-CoA desaturase inhibitors
EP2316458A1 (fr) 2004-09-20 2011-05-04 Xenon Pharmaceuticals Inc. Derives de pyridazine destines a l'inhibition du desaturase-coa-stearoyl de l'humain
US7777036B2 (en) 2004-09-20 2010-08-17 Xenon Pharmaceuticals Inc. Heterocyclic derivatives and their use as therapeutic agents
AU2005286793A1 (en) 2004-09-20 2006-03-30 Xenon Pharmaceuticals Inc. Heterocyclic derivatives for the treatment of diseases mediated by stearoyl-CoA desaturase enzymes
CN101084212A (zh) 2004-09-20 2007-12-05 泽农医药公司 杂环衍生物及其作为硬脂酰CoA去饱和酶介导剂的用途
CN101083993A (zh) 2004-09-20 2007-12-05 泽农医药公司 杂环衍生物及其作为硬脂酰CoA去饱和酶抑制剂的用途
JP2008514616A (ja) * 2004-09-24 2008-05-08 メルク エンド カムパニー インコーポレーテッド 肥満の治療のための組合せ療法
GB0510141D0 (en) * 2005-05-18 2005-06-22 Addex Pharmaceuticals Sa Novel compounds B3
BRPI0611187A2 (pt) 2005-06-03 2010-08-24 Xenon Pharmaceuticals Inc derivados aminotiazàis como inibidores da estearoil-coa desaturase humana
EP2233470B1 (fr) 2005-07-04 2011-12-07 High Point Pharmaceuticals, LLC Antagonists du receptor histamine H3
WO2007075852A2 (fr) * 2005-12-22 2007-07-05 Icagen, Inc. Antagonistes du canal calcique
EP2038256A1 (fr) 2006-05-23 2009-03-25 TransTech Pharma, Inc 6-(4-cyclopropylpiperazin-1-yl)-2'-methyl-[3,4']-bipyridine et son utilisation comme medicament
PT2079732E (pt) 2006-05-29 2012-02-02 High Point Pharmaceuticals Llc 3-(1,3-benzodioxol-5-il)-6-(4-ciclopropilpiperazin-1-il)- piridazina, os seus sais e solvatos e a sua utilização a título de antagonista do receptor h3 de histamina
US8849577B2 (en) * 2006-09-15 2014-09-30 Metabolon, Inc. Methods of identifying biochemical pathways
CN101627034B (zh) * 2007-03-16 2013-05-15 埃科特莱茵药品有限公司 氨基-吡啶衍生物作为s1p1/edg1受体激动剂
EP2014656A3 (fr) 2007-06-11 2011-08-24 High Point Pharmaceuticals, LLC Nouveaux antagonistes d'hétéocycliques h3
WO2009112033A1 (fr) * 2008-03-12 2009-09-17 Københavns Universitet (University Of Copenhagen) Utilisation d’antagonistes de récepteur npy y5 pour la prévention de l’abus de psychostimulants et d’opioïdes
BRPI0922364A2 (pt) * 2008-12-03 2017-08-29 Presidio Pharmaceuticals Inc Composto, composição farmacêutica e uso de um composto
RU2538964C1 (ru) 2010-12-17 2015-01-10 Мицубиси Танабе Фарма Корпорейшн Соединение с последовательной арициклической структурой, обладающее активностью ингибирования ацилкофермента а: диацилглицеринацилтрансферазы (dgat1)
EP2862856B1 (fr) 2012-06-15 2018-08-01 Mitsubishi Tanabe Pharma Corporation Composés d' imidazole et de triazole en tant qu'inhibiteurs de dgat-1
US10328064B2 (en) * 2014-12-23 2019-06-25 Fgh Biotech, Inc. Compositions of fatostatin based heterocyclic compounds and uses thereof
PH12022551224A1 (en) 2019-11-19 2023-06-14 Max Planck Gesellschaft Zur Fa–Rderung Der Wss E V Novel compounds for the diagnosis, teatment and prevention of diseases associated with the aggregation of alpha-synuclein

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4853383A (en) 1975-03-03 1989-08-01 Merck & Co., Inc. β-blocking substituted imidazoles
US4440774A (en) 1975-03-03 1984-04-03 Merck & Co., Inc. 3-Amino-2-hydroxypropoxyaryl imidazole derivatives
JPH0251150A (ja) * 1988-08-12 1990-02-21 Konica Corp 新規なシアンカプラーを含有するハロゲン化銀写真感光材料
DE3935514A1 (de) * 1989-10-25 1991-05-02 Boehringer Mannheim Gmbh Neue bicyclo-imidazole, verfahren zu ihrer herstellung und diese verbindungen enthaltende arzneimittel
ES2058651T3 (es) * 1990-03-30 1994-11-01 Heumann Pharma Gmbh & Co Uso derivados de guanidina para la fabricacion de un medicamento con actividad antagonista de npy.
US6562862B1 (en) 1994-10-20 2003-05-13 Eli Lilly And Company Methods of inhibiting physiological conditions associated with an excess of neuropeptide Y
KR970707101A (ko) 1994-11-07 1997-12-01 스피겔 알렌 제이 치환된 벤질아민 유도체; 신규한 부류의 신경펩타이드 y1 특이적 리간드(certain substituted benzylamine derivatives; a new class of neuropeptide y1 specific ligands)
EP0759441A3 (fr) * 1995-06-30 1999-06-30 Eli Lilly And Company Procédés de traitement des pathologies associées aux peptides neuropeptide Y
AU744297B2 (en) * 1997-07-03 2002-02-21 Neurogen Corporation Certain diarylimidazole derivatives; a new class of NPY specific ligands
WO1999048873A1 (fr) * 1998-03-25 1999-09-30 Bristol-Myers Squibb Company Agents anorexigenes d'imidazolone: derives acycliques i

Also Published As

Publication number Publication date
AR028824A1 (es) 2003-05-28
AU2935200A (en) 2000-11-17
PE20010118A1 (es) 2001-02-03
US20010039277A1 (en) 2001-11-08
UY26130A1 (es) 2000-12-29
HN2000000041A (es) 2001-02-02
GT200000057A (es) 2001-10-20
WO2000066578A1 (fr) 2000-11-09
PA8493701A1 (es) 2002-07-30
MA26730A1 (fr) 2004-12-20
US6355635B1 (en) 2002-03-12
CO5170414A1 (es) 2002-06-27
US6514966B2 (en) 2003-02-04

Similar Documents

Publication Publication Date Title
TNSN00092A1 (fr) Composes nouveaux antagonistes de npy, procede pour leur preparation et compositions pharmaceutiques les contenant
TNSN99172A1 (fr) 4-carboxyamino-2-methyl-1,2,3,4-tetrahydroquinoleines, procede pour leur preparation et compositions pharmaceutiques les contenant
TNSN00191A1 (fr) Composes nouveaux, compositions les contenant et leur utilisation dans le traitement d'une ischemie
TNSN99053A1 (fr) Hydroxamides d'acides (4-arylsulfonylamino)-tetrahydro- pyranne-4-carboxyliques), procede pour leur preparation et compositions les contenant
TNSN00036A1 (fr) Acides oxamiques nouveaux, procede pour leur preparation et compositions pharmaceutiques les contenant.
TNSN99106A1 (fr) Derives d'isothiazole nouveaux, procede pour leur preparation et compositions pharmaceutiques les contenant.
TNSN99236A1 (fr) Derives bicycliques substitues nouveaux, procede pour leur preparation et compositions pharmaceutiques les contenant.
TNSN98238A1 (fr) Macrolides nouveaux
TNSN99006A1 (fr) 4-(2-ceto-1-benzimidazolinyl) piperidines nouvelles, procede pour leur preparation et compositions pharmaceutiques les contenant
TNSN98045A1 (fr) Derives de nicotinamide nouveaux, procede pour leur preparation et compositions pharmaceutiques les contenant.
TNSN00202A1 (fr) Derives de n-[(purine - 2- yl) methyl]-sulfonamide nouveaux, procede pour leur preparation et compositions les contenant
TNSN99095A1 (fr) 4 - phenylpiperidines nouvelles, procede pour leur preparation et compositions pharmaceutiques les contenant
TNSN00028A1 (fr) Derives de quinoleine -2-one a substituant heteroaryle nouveaux procede pour leur preparation et compositions pharmaceutiques les contenant.
TNSN00228A1 (fr) Derives de benzimidazole nouveaux, et compositions les contenant
TNSN99155A1 (fr) 1-aryl-3-arylmethyl-1,8-naphtyridine-4(1h)-ones nouvelles, procede pour leur preparation et compositions pharmaceutiques les contenant
TNSN98019A1 (fr) Derives d'acide arylsulfonylaminohydroxamique, procede pour leur preparation et compositions pharmaceutiques les contenant.
TNSN99055A1 (fr) Derives bicycliques d'acide hydroxamique nouveaux, procede pour leur preparation et compositions pharmaceutiques les contenant
TNSN00239A1 (fr) DERIVES DE PYRROLO [2,3-d] PYRIMIDINE NOUVEAUX, ET COMPOSITIONS LES CONTENANT
TNSN99253A1 (fr) Composes chimiques nouveaux modulateurs de ccr5, et compositions pharmaceutiques les contenant.
TNSN99162A1 (fr) Derives de quinoleine-2-one a substituant alcynyle nouveaux, procede pour leur preparation et compositions pharmaceutiques les contenant
TNSN98082A1 (fr) DERIVES SUBSTITUES EN C - 4 DE 9 - DESOXO - 9a - aza - 9a HOMOERYTHROMYCINE A.
TNSN98017A1 (fr) Derives de sulfonyluree, procede pour leur preparation et compositions pharmaceutiques les contenant.
TNSN99169A1 (fr) Derives de 4,4-biarylpiperidine nouveaux, procede pour leur preparation et compositions pharmaceutiques les contenant
TNSN99073A1 (fr) Pyrazolopyrimidinones nouvelles, procede pour leur preparation et compositions pharmaceutiques les contenant
TNSN99031A1 (fr) Composes heterocycliques nouveaux inhibiteurs de romatases, procede pour leur preparation et compositions pharmaceutiques les contenant